Navigation Links
Delcath Announces Agreement With Institut Gustave Roussy for Launch of Hepatic CHEMOSAT Delivery System in France
Date:3/15/2012

,600 professionals working in care, research, and teaching. www.igr.fr

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study's primary endpoint of extended hepatic progression-free survival.  The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at www.delcath.com

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the future use and adoption of the CHEMOSAT
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Haemonetics Corporation (NYSE: ... , CFO & EVP-Business Development, will present at The Deutsche ... Boston, MA on May 29, 2013 ... ) The public may access Mr. Lindop,s ... About Haemonetics Haemonetics (NYSE: HAE ...
(Date:5/23/2013)... , May 23, 2013 Hearing health affects a ... younger, and remain socially and professionally engaged, he should address ... overriding message that the Better Hearing Institute (BHI) ... National Men,s Health Week , which leads up to ... runs from June 10 through June 16. ...
(Date:5/23/2013)... 23, 2013  A recently published clinical study conducted ... Texas , demonstrates that 3D mammography (breast tomosynthesis) ... The study, "Implementation of Breast Tomosynthesis ... led by Stephen L. Rose , ... American Journal of Roentgenology (AJR). The AJR ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
...  Internal Fixation Systems, Inc. (OTCQB: IFIX), ... value priced orthopedic and podiatric implants is pleased to report ... feature Internal Fixation Systems (IFS) as its feature cover ... its innovative approach to addressing the critical cost control ...
... 26, 2012 Marken announced today that it has opened ... new offices will provide the company with unique access to ... expand into new supply chain services. The two offices will ... and depot facilities and enable it unlimited 24/7 access to ...
Cached Medicine Technology:Internal Fixation Systems, Inc. Featured Cover Story in February Issue of MicroCap Review 2Marken Opens New Corporate Offices 2
(Date:5/24/2013)... 2013 Gift Card Network members ... in sustainable card material, are combining forces to ... as a sustainable gift card substrate. , The ... challenges and increase education and usage of these ... the reduction of carbon footprint and environmental impact ...
(Date:5/24/2013)... May 24, 2013 Let’s face it: very ... not uncommon for the majority of people to be uncomfortable ... due to a coffee addiction or simply genetics, yellowish or ... are so popular. , Herald Square Dental is ... effective whitening system: Venus White Max. , Teeth become ...
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... to the development of infantile myofibromatosis (IM)a disorder characterized ... tissuemay provide new therapeutic targets, according to researchers from ... findings, published in the American Journal of Human ... this debilitating disease, for which the only current treatment ... IM is an inheritied disorder that develops in infancy ...
(Date:5/24/2013)... Mike Stoler believes that there is much ... in New York. That’s why he hosts “Building ... TV. And that’s why he invited Robert Glazer, ... (ENTA)—the largest single specialty practice in the greater New ... audiology specialists and sub-specialists service communities throughout New York ...
Breaking Medicine News(10 mins):Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4
... , WEDNESDAY, Feb. 23 (HealthDay News) -- The main ... regain their ability to taste and enjoy food, according to ... could potentially lead to treatments to help some cancer patients ... to smell and taste food, which can cause them to ...
... a factory or at a rock concert, noise-induced hearing loss ... Researchers at Washington University School of Medicine in St. Louis ... in mice when given before they are exposed to loud ... hearing loss after noise exposure. While both drugs are ...
... - Understanding the genetics of bipolar disorder could lead ... with this disorder has been challenging. A ... brain protein called Piccolo in the risk for inheriting ... is a member of a protein family that includes ...
... percent of the world,s population is currently infected by hepatitis ... cirrhosis and liver cancer, and it,s the most frequent cause ... we have no traditional vaccine, but researchers at the University ... a vaccine, which provides future hope for medical protection from ...
... , WEDNESDAY, Feb. 23 (HealthDay News) -- People,s ... to stress, according to a new study. To reach ... make a speech in a laboratory in front of a ... responses were monitored during the speech, and they were later ...
... after having early-stage breast cancer, but they are at ... a new cancer, in either breast. Annual screening (a.k.a. ... but only scant evidence on screening outcomes supported this ... the American Medical Association , the most comprehensive relevant ...
Cached Medicine News:Health News:Pot Ingredient May Restore Appetite After Chemo 2Health News:2 drugs protect hearing better than 1 2Health News:A new clue to the genetics of bipolar disorder: Piccolo 2Health News:New vaccine technology protects mice from hepatitis C virus 2Health News:New vaccine technology protects mice from hepatitis C virus 3Health News:New vaccine technology protects mice from hepatitis C virus 4Health News:Screening mammograms catch second breast cancers early 2
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use....
Used for arterial and venous punctures. The tapered hub design of the catheter facilitates wire guide introduction. Supplied sterile in peel-open packages. Intended for one-time use....
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 21 gage needle stick is desired....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Medicine Products: